Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Takeda | History Defined

A New Weekly Injection Cut Repeat Blood Draws for Most Patients with a Rare Blood Cancer

FDA approved Mimrylo for polycythemia vera. In trial data, 76.9% of patients needed no blood draws during weeks 20 to 32, versus 32.9% on placebo.

Medical Daily

A Weekly Shot Spared Three in Four Blood Cancer Patients from Repeat Blood Draws, and the FDA Just Approved It

FDA approved Mimrylo for polycythemia vera, the first hepcidin-mimicking drug for a blood cancer affecting about 90,000 Americans.

Medical Daily

A Weekly Injection Could Replace Repeated Blood Draws for Some Patients with a Rare Blood Cancer

The FDA approved a first-in-class weekly injection for polycythemia vera that cut the need for repeated therapeutic blood draws in trials.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Rare Blood Disorder Drug Gains a Boxed Warning Regulators Overruled the Language Its Maker Proposed

Adzynma's US label now carries a boxed warning on neutralizing antibodies linked to deaths, added after an FDA order that Takeda contested.

Medical Daily

The First Narcolepsy Drug That Treats the Underlying Disease Is Approved but Not Yet Available to Patients

Orzeyful is approved for narcolepsy type 1, but DEA scheduling must finish first. Here is who qualifies and when it may reach pharmacies.

Medical Daily

FDA Approves First Narcolepsy Drug That Targets the Brain Signal Loss Behind the Disorder

FDA-approved Orzeyful, the first narcolepsy type 1 drug that restores orexin signaling instead of treating symptoms one at a time.

Medical Daily

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

MarketBeat

5 ‘Outstanding’ Kitchen Knives That This Michelin-Starred Chef Would Actually Recommend — They “Combine Design Elegance With Exceptional Function”

"A chef's knife is the heartbeat of my kitchen," says Petros Dimas, Domes Resorts executive chef and Makris Restaurants chef patron. Here are some standouts you can count on for precision, balance, and responsiveness

Livingetc

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Benzinga

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

Benzinga

In an uncertain world, CEOs seek growth while bracing for disruption

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly multipolar world.

Fortune

Why Takeda no longer has an 'IT department' as part of the drug maker's digital and data transformation

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

‘If they don’t get care, they die’: the woman who runs the world’s largest kidney dialysis company

Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients

The Guardian - AU

‘Feels quite cruel’: Australians with ADHD scrambling to find medication amid shortage

Patient says pharmacists she went to were suspicious because Vyvanse is a stimulant, causing her the ‘most dehumanising medical experience’ of her life

Barchart

3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

The Independent UK

Health officials tell US doctors to be alert for dengue as cases ramp up worldwide

U.S. health officials are warning doctors to be alert for dengue cases as the tropical disease breaks international records

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

UK swapped to fatal US blood products to save money, minutes suggest

Exclusive: contaminated blood campaigners say internal 1976 Immuno AG document proves British government negligence

The Hindu

Hyderabad’s Biological E. to make 50 million doses of Takeda’s dengue vaccine

Takeda and Hyderabad-based vaccine maker Biological E. have formed a strategic partnership to accelerate access to the Japanese firm’s QDENGA dengue vaccine (TAK-003) multi-dose vials.

StockNews.com

3 Outsourcing Stocks With Potential to Make Gains

The outsourcing sector is well-placed to thrive due to its ability to provide cost-effective solutions, access to specialized skills, focus on core business activities, and enhanced productivity. Therefore, it could be wise to invest in quality outsourcing stocks Cognizant (CTSH), Stride (LRN), and Barrett Business Services (BBSI) for substantial gains.…

The Hindu

Regulator issues alert over sale of falsified versions of 2 drugs

Drugs regulator Drugs Controller General of India has directed States and Union Territories to keep vigil on sale and distribution of falsified versions of two drugs, liver medication Defitelio and Takeda’s cancer drug Adcetris after alerts from World Health Organization

Fortune

Digitalization could be the answer to better health care for patients. But first, they need to trust it

Takeda Pharmaceutical chief digital trust officer Mike Towers says his industry has been slow to adapt, but is accelerating fast.

The Conversation

'The dirty disease' – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

Daily Mirror

Dengue fever warning to Brits heading off to popular holiday resorts this summer

Brits planning to travel abroad are being warned about the risks of potentially deadly dengue fever - a disease spread by Asian tiger mosquitoes and which has been detected in the likes of Ibiza and southern France

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.